Osimertinib plus chemotherapy in uncommon EGFRm NSCLC

Trial Identifier: D5161C00017
Sponsor: AstraZeneca
NCTID:: NCT05215951
Start Date: July 2022
Primary Completion Date: March 2023
Study Completion Date: March 2023
Condition: Lung Cancer

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
CN Changsha, CN, 430033
CN Chengdu, CN, 610072
CN Chengdu, CN, 610042
CN Chengdu, CN, 610041
CN Harbin, CN, 150049
CN Mianyang, CN, 621000
CN Nan Chong, CN, 637000
CN Wenzhou, CN
CN Yibin, CN, 644000
CN Zhengzhou, CN, 450000